Clinical Lymphoma, Myeloma & Leukemia

Pomalidomide/daratumumab/dexamethasone in relapsed or refractory multiple myeloma: Final overall survival from MM-014

Frontiers in Immunology

Cost-per-responder analysis of patients with lenalidomide-refractory multiple myeloma receiving ciltacabtagene autoleucel in CARTITUDE-4

PharmacoEconomics

Healthcare resource utilization and associated costs during the first 5 years after diagnosis and at the end of life: A nationwide cohort study of patients with multiple myeloma in Finland

The Oncologist

Evaluating early intervention in smoldering myeloma clinical trials: A systematic review

NPJ Digital Medicine

Joint AI-driven event prediction and longitudinal modeling in newly diagnosed and relapsed multiple myeloma

Journal of Blood Medicine

Secondary polycythemia may be an early clinical manifestation of multiple myeloma: A case report

Japanese Journal of Radiology

Review of whole-body magnetic resonance imaging in multiple myeloma

Frontiers in Oncology

Advancements in microenvironment-based therapies: Transforming the landscape of multiple myeloma treatment

Journal of the Advanced Practitioner in Oncology

Patient-reported outcomes with belantamab mafodotin treatment in patients with triple-class refractory multiple myeloma

Cancer Discovery

CAR T-cell availability for multiple myeloma improving but still limited